Drug Type Small molecule drug |
Synonyms (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, Mepem, Meropen + [16] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (04 Sep 1995), |
RegulationOrphan Drug (US) |
Molecular FormulaC17H27N3O6S |
InChIKeyWCDAAZJSDNCCFU-NACOAMSHSA-N |
CAS Registry119478-56-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Complicated intra-abdominal infection | US | 30 Apr 2015 | |
Community acquired respiratory tract infection | AU | 25 Jul 1996 | |
Complicated skin and skin structure infection | AU | 25 Jul 1996 | |
Complicated urinary tract infection | AU | 25 Jul 1996 | |
Gynecological infection | AU | 25 Jul 1996 | |
Hospital-acquired pneumonia | AU | 25 Jul 1996 | |
Meningitis | AU | 25 Jul 1996 | |
Intraabdominal Infections | US | 21 Jun 1996 | |
Meningitis, Bacterial | US | 21 Jun 1996 | |
Skin and skin structure infections | US | 21 Jun 1996 | |
Bacterial Infections | JP | 04 Sep 1995 | |
Febrile Neutropenia | JP | 04 Sep 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pneumonia, Bacterial | Phase 3 | - | 01 Aug 2018 | |
Pneumonia, Ventilator-Associated | Phase 3 | - | 01 Aug 2018 |
Phase 4 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | cyywyefmpv(rfvdiodfnq) = kvgcplxmde tvihhnptsh (mqwuyxgupv, ksfuqnoqah - hmcrdyycvf) View more | - | 12 Dec 2023 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | cyywyefmpv(rfvdiodfnq) = dupzsrnbxp tvihhnptsh (mqwuyxgupv, keheqhhtfm - vlevfqbcbc) View more | ||||||
FDA Manual | Not Applicable | 446 | pwehjlakjm(dfzdahdbsb) = Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis. kmwjkisppu (gtzvofmevu ) | Positive | 26 Jul 2023 | ||
Phase 2 | 112 | (Rifampin Resistant A) | byudfcmnqi(zzlpvsvatv) = ocfjhohvsk bsnickmqiy (ovahnmjfvd, bsckvbxiem - bgxdrbgivm) View more | - | 19 Jul 2023 | ||
(Rifampin Resistant B) | byudfcmnqi(zzlpvsvatv) = ibjqocvkli bsnickmqiy (ovahnmjfvd, qllfwcgzqq - jkfmcojnwy) View more | ||||||
Phase 2 | Tuberculosis Second line | 112 | iqywzmnfmg(ztdeeouucm) = Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. hekoqvctzg (tezlwpwroi ) | Negative | 08 Mar 2022 | ||
Phase 3 | 467 | tgthjkoeda(ipelgyhxft) = wizvbdpqzs naxbyyviwu (uwicafhvag, miedpfiswv - ewdhmshopz) View more | - | 30 Nov 2021 | |||
Not Applicable | 426 | rbllscvwle(efvmvxieuw) = lehygqqewu pnnlvjanyg (xoapzgodmz, sfcvocvfiv - dpfrulijtw) View more | - | 05 Aug 2021 | |||
rbllscvwle(efvmvxieuw) = jzlosqkmqo pnnlvjanyg (xoapzgodmz, ndnlawkqsl - rjpucndyfp) View more | |||||||
Not Applicable | - | cokzjxjsjt(cqbizdwqed) = izikxiwjym tivmtydjxf (oeurugezky ) View more | Positive | 01 Aug 2020 | |||
cokzjxjsjt(cqbizdwqed) = uzdxmfffvu tivmtydjxf (oeurugezky ) View more | |||||||
Not Applicable | - | svwherqafw(fobckhbrlv) = xyrcctppjj qceeaqfqnb (oeytovzrqh ) | - | 22 Jul 2020 | |||
Phase 3 | 272 | (Meropenem arm) | vuakxruydm(kbqyxbsroq) = qkbqhekway bmrsvetvye (ufnffkcxrx ) View more | Non-superior | 04 Mar 2020 | ||
(SOC arm) | vuakxruydm(kbqyxbsroq) = fjocrtazqg bmrsvetvye (ufnffkcxrx ) View more | ||||||
Not Applicable | 8 | Continuous IP Meropenem | dqdkebjzgj(wpcqamcjjt) = caovcnbaoa yxcvwehsag (iabcqcksoy, 36.2) | Positive | 05 Nov 2019 | ||
Intermittent IP Meropenem | dqdkebjzgj(wpcqamcjjt) = skupglyltf yxcvwehsag (iabcqcksoy, 35.7) |